Therapeutic options in the treatment of clozapine-induced sialorrhea

Pharmacotherapy

Volumn 20, Issue 9 I, 2000, Pages 1092-1095

  Rogers, D P ^a   Shramko, J K ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE;

DRUG INDICATION; DRUG USE; HUMAN; HYPERSALIVATION; MENTAL PATIENT; PATHOPHYSIOLOGY; REVIEW;

EID: 0033818202     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.13.1092.35036     Document Type: Review

References (19)

1. The Clozapine National Registry System: Forty years of risk management
2. The side effects of clozapine: A four year follow-up study
3. Salivary flow-rate and composition in schizophrenic patients on clozapine: Subjective reports and laboratory data
4. Aspiration pneumonia secondary to clozapine-induced sialorrhea
5. Clonidine treatment of clozapine-induced hypersalivation
6. Drugs acting at synaptic and neuroeffector junctional sites
7. Effect of adrenergic agents on salivary composition
8. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors in CHO-K1 cells
9. Clozapine is a potent and selective muscarinic M4 receptor agonist
10. The effect of clozapine on saliva flow rate: A pilot study
11. Amitriptyline in clozapine-induced sialorrhea
12. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine
13. Atropine, scopolamine and related antimuscarinic drugs
14. Pirenzepine for clozapine-induced hypersalivation
15. Trihexyphenidyl treatment of clozapine-induced hypersalivation
16. Clozapine and sialorrhea: A new intervention for this bothersome and potentially dangerous side effect
17. Hypersalivation and clozapine
18. The control of oral secretions in bulbar ALS/MND